Stada Takes ViruProtect To Russia And Beyond
Germany's Stada has expanded its deal with Enymatica to take the latter's ViruProtect common cold brand into Russia, the CIS and beyond.
You may also be interested in...
RB CEO Laxman Narasimhan sees the potential for the company to establish a global supplements business built on the successes it has enjoyed in the US and China. The comments came as RB reported solid growth in the third quarter, despite struggles for its OTC brands.
Bayer invests $8m in medical dermatology specialist Azitra to advance development of OTC and cosmetic products harnessing the skin microbiome.
Teva subsidiary Ratiopharm has secured EMA backing for the EU-wide switch of allergy drug desloratadine.